Its progression is fast ... A symptom of multiple sclerosis (MS), optic neuritis causes a similar loss of vision in one or, rarely, both eyes. Unlike LHON, though, in most cases, optic neuritis ...

While the trials initially failed to demonstrate slowing disease progression ... is developing to treat acute optic neuritis, a common symptom of multiple sclerosis (MS) that can lead to vision ...

The exact cause of this is unknown. Optic neuritis also affects about half of people with multiple sclerosis (MS), a progressive neurologic disorder. It's frequently the first symptom of the condition ...

Get Instant Summarized Text (Gist) Tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, shows potential in reducing disability progression in non-relapsing progressive multiple sclerosis (MS ...

Sanofi’s tolebrutinib has been shown to delay disability progression in multiple sclerosis (MS) patients, according to phase 3 results published in the New England Journal of Medicine (NEJM). The late ...

Optic neuritis occurs frequently in patients with multiple sclerosis and often is the first manifestation of the disease. It is characterized by a decrement in visual acuity, loss of color vision ...

More information: Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis, New England Journal of Medicine (2025).

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

AI will unlock the untapped potential of the treasure trove of hospital information to provide unprecedented insights into MS progression and how treatments work and affect the brain." The current ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

To learn more about the Phase 3 DIAMOND trials, please visit diamondtrial.com.